NASDAQ$OPK
OPKO Health Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
OPKO Health's Q3 2021 financial results were reported, with increased operating and net income despite a decrease in total revenues.
OPKO Health reported a decrease in consolidated total revenues to $385.8 million compared to $428.1 million for the same period in 2020. However, operating income increased by 72% to $37.8 million, and net income was $28.7 million, or $0.04 per diluted share.
- Health Canada approved NGENLA™ for pediatric growth hormone deficiency.
- BioReference Laboratories processed approximately 2.2 million COVID-19 PCR tests.
- BRL acquired the U.S. Ariosa centralized laboratory prenatal testing business from Roche.
- Completed enrollment in Phase 2 trial evaluating RAYALDEE® as a treatment for symptomatic COVID-19 outpatients.
Headline financials
Revenue & EPS history
OPKO Health · Revenue · Quarterly
$386M
Revenue by segment
OPKO Health · $377M total across 2 segments · Q3 2021
- Services$340M—90.2%
- Products$36.9M—9.8%
Forward guidance
OPKO Health's global regulatory applications for somatrogon are advancing, with action dates expected in the U.S., Europe, and Japan during the first half of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
-0.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-0.2%
Avg return
30 days after
44%
27 / 61 earnings
Positive
+26.8%
Q1 2018
Best reaction
-17.7%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.8% | -8.3% | +19.2% | |
| Q4 2025 | +2.5% | +0.0% | -6.7% | |
| Q3 2025 | -2.9% | -4.3% | -2.9% | |
| Q1 2025 | -2.2% | -7.2% | -1.4% | |
| Q4 2024 | +6.7% | +19.0% | +4.3% | |
| Q3 2024 | +3.4% | +9.5% | +8.2% | |
| Q2 2024 | +6.7% | +11.9% | +16.4% | |
| Q1 2024 | -5.3% | -3.0% | +1.5% | |
| Q4 2023 | -1.1% | -1.0% | +20.0% | |
| Q3 2023 | -0.7% | -6.7% | +18.5% | |
| Q2 2023 | +13.1% | +6.8% | +2.8% | |
| Q1 2023 | +15.0% | +26.5% | -1.4% | |
| Q4 2022 | +0.0% | +7.5% | +22.6% | |
| Q3 2022 | -14.8% | -9.3% | -25.8% | |
| Q2 2022 | -6.6% | +2.9% | -12.7% | |
| Q1 2022 | +11.8% | +15.6% | +8.4% | |
| Q4 2021 | +7.4% | +3.7% | +17.8% | |
| Q3 2021 | +5.9% | +16.2% | +15.4% | |
| Q2 2021 | -11.6% | -7.2% | -0.8% | |
| Q1 2021 | -3.7% | -4.2% | -10.5% | |
| Q4 2020 | -13.6% | -18.0% | -12.9% | |
| Q3 2020 | -12.0% | -11.0% | +3.3% | |
| Q2 2020 | -11.1% | -7.4% | -42.3% | |
| Q1 2020 | -15.2% | +3.9% | +2.2% | |
| Q4 2019 | +3.6% | +12.2% | +0.7% | |
| Q3 2019 | -2.0% | -2.6% | +5.3% | |
| Q2 2019 | -2.1% | -6.2% | -4.6% | |
| Q1 2019 | -16.1% | -14.9% | -22.1% | |
| Q4 2018 | -9.9% | -5.7% | -7.8% | |
| Q3 2018 | +6.7% | -7.4% | -6.0% | |
| Q2 2018 | -0.4% | -1.6% | +1.5% | |
| Q1 2018 | +26.8% | +37.8% | +23.5% | |
| Q4 2017 | -0.6% | +0.9% | -6.5% | |
| Q3 2017 | -17.7% | -20.1% | -20.2% | |
| Q2 2017 | +1.7% | -1.3% | -1.6% | |
| Q1 2017 | -3.4% | -0.8% | -13.7% | |
| Q4 2016 | -11.5% | -9.3% | -4.6% | |
| Q3 2016 | -6.6% | -3.4% | +11.8% | |
| Q2 2016 | +0.3% | -0.5% | -5.1% | |
| Q1 2016 | +6.7% | — | — | |
| Q4 2015 | +0.4% | — | — | |
| Q3 2015 | +7.6% | — | — | |
| Q2 2015 | -13.7% | — | — | |
| Q1 2015 | +4.8% | — | — | |
| Q4 2014 | -2.7% | — | — | |
| Q3 2014 | +2.5% | — | — | |
| Q2 2014 | -4.0% | — | — | |
| Q1 2014 | +8.4% | — | — | |
| Q4 2013 | -0.6% | — | — | |
| Q3 2013 | -1.4% | — | — | |
| Q2 2013 | +3.7% | — | — | |
| Q1 2013 | +3.4% | — | — | |
| Q4 2011 | -4.0% | — | — | |
| Q1 2011 | +1.3% | — | — | |
| Q1 2012 | +2.7% | — | — | |
| Q4 2009 | -2.6% | — | — | |
| Q3 2011 | -2.3% | — | — | |
| Q2 2011 | -3.3% | — | — | |
| Q4 2010 | -3.3% | — | — | |
| Q3 2010 | +0.7% | — | — | |
| Q1 2010 | +9.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro